LAVIOLETTE PAUL A 4
4 · PULSE BIOSCIENCES, INC. · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
Pulse Biosciences (PLSE) CEO Paul Laviolette Buys 15,000 Shares
What Happened
Paul A. Laviolette, CEO of Pulse Biosciences (PLSE), purchased 15,000 shares on May 11, 2026 at $19.69 per share for a total cost of $295,350. The transaction is reported as a purchase (code P) and represents an insider buy rather than a sale.
Key Details
- Transaction date: 2026-05-11; Price: $19.69; Shares: 15,000; Total value: $295,350.
- Transaction code: P (purchase).
- Shares were acquired through the company’s at‑the‑market (ATM) equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC.
- Footnotes: (1) Acquisition occurred under the ATM program and during an open trading window in compliance with applicable securities laws. (2) Shares were acquired in a negotiated manner at the prevailing market bid price or better.
- Shares owned after the transaction: not specified in the provided filing.
- Filing timeliness: Reported on 2026-05-11 (same date as transaction), indicating a timely Form 4 filing.
Context
Insider purchases can be viewed as a positive signal because executives are personally investing in company stock, though they do not prove future performance. This buy was executed via the company’s ATM program (a mechanism for issuing/selling shares into the market with a sales agent), rather than as an option exercise or gift.
Insider Transaction Report
Form 4
LAVIOLETTE PAUL A
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
[F1][F2]2026-05-11$19.69/sh+15,000$295,350→ 15,000 total
Footnotes (2)
- [F1]The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws.
- [F2]The shares reported herein were acquired in a negotiated through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale.
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact|2026-05-11